Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Bristol Gate's 2025 Annual Letter acknowledges underperformance caused by maintaining a diversified portfolio during a period of massive, narrow AI concentration. To enhance their...
— Achilleas Taxildaris
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Eli Lilly and Company
The company remains a premier growth compounder in the highly underserved global diabetes and obesity therapeutic markets. While the market...
Eli Lilly is the eleventh largest holding. Global branded pharmaceutical...
Eli Lilly is a global pharmaceutical leader commanding major commercial franchises in diabetes, metabolic dysfunction, oncology, immunology, and neuroscience. The manager initiated...